| Trial ID: | L6324 |
| Source ID: | NCT04586907
|
| Associated Drug: |
Ly3537021
|
| Title: |
A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Healthy|Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: LY3537021|DRUG: Placebo
|
| Outcome Measures: |
Primary: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration, A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module, Baseline through Day 119 (Part A) and Day 57 (Part B) | Secondary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3537021, PK: AUC of LY3537021, Predose Day 1 through Day 119 (Part A) and Day 57 (Part B)|PK: Maximum Concentration (Cmax) of LY3537021, PK: Cmax of LY3537021, Predose Day 1 through Day 119 (Part A) and Day 57 (Part B)
|
| Sponsor/Collaborators: |
Sponsor: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
85
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2020-11-23
|
| Completion Date: |
2021-11-30
|
| Results First Posted: |
|
| Last Update Posted: |
2021-12-17
|
| Locations: |
Lilly Centre for Clinical Pharmacology, Singapore, 138623, Singapore
|
| URL: |
https://clinicaltrials.gov/show/NCT04586907
|
